08:00 , Jan 27, 2014 |  BC Week In Review  |  Clinical News

Zoenasa Rectal Suspension: Completed Phase II enrollment

Altheus completed enrollment of about 120 patients in the double-blind, U.S. Phase II ZA201 trial comparing Zoenasa Rectal Gel vs. mesalamine enema for 6 weeks. Data are expected in March or early April. The product...
07:00 , Oct 22, 2012 |  BC Week In Review  |  Financial News

Altheus Therapeutics financial update

Altheus raised $400,000 in the second close of a series B round, bringing the total raised to $3.4 million. SeedStep Angels and the OkAngel Sidecar Fund participated. Altheus raised $3 million in a first close...
07:00 , Sep 3, 2012 |  BC Week In Review  |  Clinical News

Zoenasa Rectal Suspension: Phase II started

Altheus began the double-blind, U.S. Phase II ZA201 trial to compare Zoenasa Rectal Gel vs. mesalamine rectal enema for 6 weeks in about 120 patients. The product has Orphan Drug designation in the U.S. to...
08:00 , Jan 17, 2011 |  BC Week In Review  |  Clinical News

Zoenasa Rectal Suspension: Phase I data

A double-blind, mesalamine enema-controlled, U.S. Phase I trial in 6 patients showed that 2 doses of Zoenasa Rectal Suspension did not lead to any serious adverse events. The product has Orphan Drug designation in the...